scholarly journals ERS International Congress, Madrid, 2019: highlights from the Clinical Techniques, Imaging and Endoscopy Assembly

2020 ◽  
Vol 6 (2) ◽  
pp. 00116-2020
Author(s):  
Julia d'Hooghe ◽  
Haizea Alvarez Martinez ◽  
Pia Iben Pietersen ◽  
Christian B. Laursen ◽  
Nicole Hersch ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Infectious Diseases ◽  
Lung Disease ◽  
Current Knowledge ◽  
International Congress ◽  
Therapeutic Approaches ◽  
European Respiratory Society ◽  
Study Results ◽  
Diagnostic Approaches

This manuscript summarises the highlights from Assembly 14, “Clinical techniques, imaging and endoscopy”, which were presented at the 2019 European Respiratory Society (ERS) International Congress in Madrid, Spain. Novel diagnostic approaches and innovative therapeutic strategies in patients with lung cancer, interstitial lung disease, obstructive airway disorders and infectious diseases are discussed. The authors from the different Assembly 14 subgroups focus on the key take-home messages given new study results, and place them in the context of current knowledge in these areas.At the 2019 ERS International Congress, encouraging results of numerous trials in the field of interventional pulmonology, imaging and ultrasound were presented. Key topics included novel diagnostic and therapeutic approaches in patients with lung cancer, interstitial lung disease, obstructive airway disorders and infectious diseases.

scholarly journals ERS international congress 2020: highlights from the “Clinical techniques, imaging and endoscopy” assembly

2021 ◽  
pp. 00118-2021
Author(s):  
Pia Iben Pietersen ◽  
Bibi Klap ◽  
Nicole Hersch ◽  
Christian B. Laursen ◽  
Simon Walsh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Infectious Diseases ◽  
Lung Disease ◽  
Therapeutic Strategies ◽  
European Respiratory Society ◽  
Scientific Discussion ◽  
Diagnostic Approaches ◽  
Selection Of

The European Respiratory Society (ERS) congress in the year 2020, a year dominated by the SARS-CoV-2 pandemic, was the first virtual congress that was ever planned with an innovative and interactive congress programme upfront. It was a large, novel platform for scientific discussion and presentations of cutting-edge innovative developments. This manuscript summarises a selection of the scientific highlights from the “Clinical techniques, imaging and endoscopy” Assembly 14. In addition to presentations on the important role of bronchoscopy, imaging and ultrasound techniques in the field of SARS-CoV-2 infection, novel diagnostic approaches and innovative therapeutic strategies in patients with lung cancer, interstitial lung disease, obstructive airway disorders and infectious diseases were also discussed.

scholarly journals ERS International Congress 2020 virtual: highlights from the Respiratory Intensive Care Assembly

2021 ◽  
pp. 00214-2021
Author(s):  
Camille Rolland-Debord ◽  
Alexander D'Haenens ◽  
Leire Mendiluce ◽  
Lydia Spurr ◽  
Shruthi Konda ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Respiratory Failure ◽  
Interstitial Lung Disease ◽  
Acute Respiratory Failure ◽  
Lung Disease ◽  
Early Career ◽  
International Congress ◽  
European Respiratory Society ◽  
Diagnostic Strategies

During the virtual European Respiratory Society (ERS) Congress 2020, early career members summarized the sessions organized by the Respiratory Intensive Care Assembly. The topics covered included diagnostic strategies in patients admitted to the Intensive Care unit (ICU) with acute respiratory failure, with a focus on patients with interstitial lung disease and for obvious reasons, SARS-CoV2 infection. These sessions are summarized in this paper, with take-home messages highlighted.

scholarly journals ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly

2022 ◽  
pp. 00640-2021
Author(s):  
Sabina A. Guler ◽  
Sara Cuevas-Ocaña ◽  
Mouhamad Nasser ◽  
Wim A. Wuyts ◽  
Marlies S. Wijsenbeek ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Lung Diseases ◽  
Interstitial Lung Diseases ◽  
Early Career ◽  
International Congress ◽  
European Respiratory Society ◽  
Patient Pathway ◽  
Selection Of

This article provides an overview of scientific highlights in the field of interstitial lung disease (ILD), presented at the virtual European Respiratory Society Congress 2021. A broad range of topics was discussed this year, ranging from translational and genetic aspects to novel innovations with the potential to improve the patient pathway. Early Career Members summarize a selection of interesting findings from different congress sessions, together with the leadership of Assembly 12 – Interstitial Lung Disease.

scholarly journals Management of Myositis-Associated Interstitial Lung Disease

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 347
Author(s):  
Tomoyuki Fujisawa
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Current Knowledge ◽  
Strong Predictor ◽  
Calcineurin Inhibitors ◽  
Pulmonary Involvement ◽  
Trna Synthetase ◽  
Evidence Based Guidelines ◽  
Substantial Heterogeneity

Idiopathic inflammatory myopathies, including polymyositis (PM), dermatomyositis (DM), and clinically amyopathic DM (CADM), are a diverse group of autoimmune diseases characterized by muscular involvement and extramuscular manifestations. Interstitial lung disease (ILD) has major pulmonary involvement and is associated with increased mortality in PM/DM/CADM. The management of PM-/DM-/CADM-associated ILD (PM/DM/CADM-ILD) requires careful evaluation of the disease severity and clinical subtype, including the ILD forms (acute/subacute or chronic), because of the substantial heterogeneity of their clinical courses. Recent studies have highlighted the importance of myositis-specific autoantibodies’ status, especially anti-melanoma differentiation-associated gene 5 (MDA5) and anti-aminoacyl tRNA synthetase (ARS) antibodies, in order to evaluate the clinical phenotypes and treatment of choice for PM/DM/CADM-ILD. Because the presence of the anti-MDA5 antibody is a strong predictor of a worse prognosis, combination treatment with glucocorticoids (GCs) and calcineurin inhibitors (CNIs; tacrolimus (TAC) or cyclosporin A (CsA)) is recommended for patients with anti-MDA5 antibody-positive DM/CADM-ILD. Rapidly progressive DM/CADM-ILD with the anti-MDA5 antibody is the most intractable condition, which requires immediate combined immunosuppressive therapy with GCs, CNIs, and intravenous cyclophosphamide. Additional salvage therapies (rituximab, tofacitinib, and plasma exchange) should be considered for patients with refractory ILD. Patients with anti-ARS antibody-positive ILD respond better to GC treatment, but with frequent recurrence; thus, GCs plus immunosuppressants (TAC, CsA, azathioprine, and mycophenolate mofetil) are often needed in order to achieve favorable long-term disease control. PM/DM/CADM-ILD management is still a therapeutic challenge for clinicians, as evidence-based guidelines do not exist to help with management decisions. A few prospective clinical trials have been recently reported regarding the treatment of PM/DM/CADM-ILD. Here, the current knowledge on the pharmacologic managements of PM/DM/CADM-ILD was mainly reviewed.

scholarly journals Risk factors for acute exacerbation in lung cancer complicated by interstitial lung disease with slight reticular shadows

2021 ◽  
Author(s):  
Yutaka Takahara ◽  
Takuya Tanaka ◽  
Yoko Ishige ◽  
Ikuyo Shionoya ◽  
Kouichi Yamamura ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Acute Exacerbation
Sign in / Sign up

Export Citation Format

Share Document